Since they were established in December 2021, COVID Medicines Delivery Units have provided antiviral or monoclonal antibody treatments to over 43,000 patients in England. Of these, over 20,100 patients have been treated with antivirals. The clinical access policies specify that the oral antivirals molnupiravir and nirmatrelvir+ritonavir must be administered within five days of the patient starting to experience symptoms. Over 95% of eligible non-hospitalised patients who have received an antiviral treatment to date were treated within five days from the onset of symptoms. However, the antiviral infusion remdesivir is suitable to be administered within seven days of the patient becoming symptomatic.